Get started
Author

Rachel Wilcox

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
2021 · Vanessa A. Fabrizio, Jaap Jan Boelens, et al. · Blood Advances · 120
PDF
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
2021 · Vanessa A. Fabrizio, Christine L. Phillips, et al. · Blood Advances · 79
PDF
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
2022 · Liora M. Schultz, Anne Eaton, et al. · Journal of Clinical Oncology · 73
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
2022 · Amy Moskop, Lauren Pommert, et al. · Blood Advances · 66
PDF
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
2022 · Heather E. Stefanski, Anne Eaton, et al. · Blood Advances · 49
Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)
2020 · Liora M. Schultz, Christina Baggott, et al. · Blood · 38
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia
2021 · Jenna Rossoff, Christina Baggott, et al. · Blood · 15
An Evaluation of Potential Inhibition of CYP3A4/5 and CYP2C9 Enzymatic Activity by Boswellia serrata Extract
2019 · Amy L. Roe, Rachel Wilcox, et al. · Applied In Vitro Toxicology · 9
PDF
Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release
2020 · Jenna Rossoff, Christina Baggott, et al. · Blood · 8
Immune Reconstitution and Infections in the Real-World Use of Tisagenlecleucel in Pediatric and Young Adult ALL
2021 · Amy Moskop, Julie-An Talano, et al. · Transplantation and Cellular Therapy · 4
Real-World Use of Tisagenlecleucel in Infant Acute Lymphoblastic Leukemia
2021 · Amy Moskop, Erin Breese, et al. · Transplantation and Cellular Therapy · 3
Post-Relapse Outcomes Following Tisagenlecleucel: Poor Survival, Despite Current Salvage Therapies: Results from the Pediatric Real World CAR Consortium (PRWCC)
2021 · Heather E Stefanski, Michael R. Verneris, et al. · Transplantation and Cellular Therapy · 3
Predictive Value of Next-Generation Sequencing (NGS) Following Tisagenlecleucel in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia
2021 · Liora Schultz, Christina Baggott, et al. · Transplantation and Cellular Therapy · 2
Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
2022 · Anthony J Ross, Christina Baggott, et al. · Blood · 1
CAR-Associated Hemophagocytic Lymphohistiocytosis (HLH) with Use of Commercial Tisagenlecleucel in the Pediatric Real World CAR Consortium (PRWCC): Risk Factors and Outcomes
2022 · Kevin O. McNerney, Stephanie Si Lim, et al. · Transplantation and Cellular Therapy · 1
Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
2022 · Vanessa A. Fabrizio, Kristen Miller, et al. · Blood
Real-World Treatment of Pediatric Patients with Relapsed/Refractory CNS B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel
2021 · Vanessa A Fabrizio, Christine L Phillips, et al. · Transplantation and Cellular Therapy
Works count: 17
Citation count: 471
H-index: 8
I10-index: 7
Year
Topic
Type